Following up on my post of yesterday:
"Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients."
here is another Italian study from 2016 [1] - but from a different team (un laboratorio diverso).
"Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone"
In my series of posts on inflammation 2 years ago, there is nothing on the platelets-to-lymphocyte ratio (PLR). Perhaps it's considered more important in Italy, but I don't recall seeing references to the PLR before yesterday.
Anyway, for those who are tracking their PLR:
"A total of 230 mCRPC patients treated abiraterone were included. SII {systemic immune-inflammation index} ≥ 535, NLR {neutrophil-to-lymphocyte ratio} ≥ 3 and PLR {platelets-to-lymphocyte ratio} ≥ 210 were considered as elevated levels (high risk groups)."
"A systemic immune-inflammation index (SII) based on neutrophil (N), lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid tumors."
"Discussion
"Our results confirmed the activity of abiraterone in post-docetaxel setting in routinely clinical practice with a PSA response rate of 44.5% and a median OS of 17.3 months comparable to results of the pivotal phase III clinical trial (de Bono et al., 2011). The prognostic significance of NLR, PLR, and percentage of lymphocytes evaluate before systemic treatment was shown in several tumors (De Giorgi et al., 2012; Templeton et al., 2014; Cannon et al., 2015; Rossi et al., 2015), while SII to date has been evaluated before antiangiogenic agents only in CRC and RCC (Lolli et al., 2016; Passardi et al., 2016). Herein, we reported for the first time SII to be an independent predictor of OS for patients with mCRPC treated with abiraterone, a recently approved hormonal therapy in mCRPC. Its ability to predict OS was higher than conventional parameters such as Gleason score (Table Table22). We also confirmed previous data on the OS prediction ability of NLR in these patients (Leibowitz-Amit et al., 2014), whereas PLR showed a borderline significance in the multivariate analysis (HR = 1.41, p = 0.068). Our results suggest a possible prominent prognostic role for neutrophil levels, included in SII and NLR, but not in PLR."
Inflammation due to chronic NF-kB activation in cancer cells can be curbed by inhibiting NF-kB. Common otc polyphenols have been found to inhibit NF-kB in the lab. It is an easy experiment on one's self to take a generous mix of polyphenols for a month, say, & retest.
-Patrick
